Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Systemic treatment for advanced, non-resectable pancreatic cancer still having minimal impact
on the survival of patients. Even with the application of more potent gemcitabine-based
regimens, survival of more than 1 year is uncommon for advanced disease. Accordingly, there
is substantial unmet needs for the improvement of treatment options. The combination and
simultaneous application of tumor-targeted L19IL2 with gemcitabine could result in improved
anti-cancer efficacy, based on preliminary clinical and strong preclinical data.
The primary purpose of this Phase I study is to define a safe and potentially more active
treatment regimen of L19IL2 (escalating doses) combined with gemcitabine for advanced
pancreatic cancer patients. Also, early signs of anticancer responses of the
L19IL2/gemcitabine regimen will be assessed and compared to historical controls (gemcitabine
monotherapy).